Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group
Advanced solid tumors represent a significant challenge in oncology, characterized
by their resistance to conventional therapies and their potential to metastasize,
leading to poor prognosis for patients. These tumors are often defined
by their stage, typically stage III or IV, indicating local invasion or
distant spread. Common types include advanced stages of breast, lung,
colorectal, and pancreatic cancers, among others.
Advanced solid tumors studies are a novel design in oncology clinical
trials that test the effect of a drug targeting a specific mutation or
molecular alteration across multiple cancer types. Unlike traditional
clinical trials that focus on a single cancer type, basket studies group
patients based on the presence of a particular biomarker, regardless of
where the cancer originated in the body.
Key features of these studies include:
- Biomarker-driven approach
- Multiple cancer types in one trial
- Usually single-arm design
- Potential for faster drug development
These studies are particularly useful for rare cancers and for evaluating
targeted therapies. They can provide valuable insights into the efficacy
of a treatment across various tumor types that share a common genetic
alteration.
Providence Medical Group is currently enrolling patients for the following
advanced solid tumor clinical trials:
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate
the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy
and in Combination with Pembrolizumab in Subjects with Solid Tumors or Lymphoma
Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician:
Ian Anderson, MD
Study Coordinator: Melissa Ulrich //
melissa.ulrich@providence.org // 707-521-3830
Study Resources:
Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression
Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA
A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug
Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono
MS202329-0010 PROCEADE)
Phase III trial of single fraction stereotactic radiosurgery (SRS) versus
fractionated SRS (FSRS) for intact brain metastases